Table 2.
Multivariable Analysis for Overall, CRS, Rapid Onset of CRS, and ICANS
| Variable | N | OR (95% CI) | P Value |
|---|---|---|---|
| CRS (no versus yes) | |||
| Sex | .006 | ||
| Female | 688 | 1 | |
| Male | 1218 | 0.72 (0.57–0.91) | .006 |
| Elevated LDH prior to CAR-T | .002 | ||
| No | 722 | 1 | |
| Yes | 832 | 1.56 (1.23–2.00) | <.001 |
| Not reported | 352 | 1.23 (0.89–1.68) | .209 |
| CAR-T product | <.001 | ||
| Tisa-cel | 478 | 1 | |
| Axi-cel | 1428 | 4.61 (3.65–5.81) | <.001 |
| Severe CRS (≥3 grade versus <3 grade and no CRS) | |||
| Age | .005 | ||
| <65 years | 1061 | 1 | |
| ≥65 years | 841 | 1.60 (1.15–2.23) | .005 |
| KPS prior to CAR-T | <.001 | ||
| 90–100 | 738 | 1 | |
| 80 | 547 | 1.63 (1.05–2.54) | .031 |
| <80 | 370 | 3.32 (2.16–5.10) | <.001 |
| Not reported | 247 | 1.53 (0.87–2.72) | .143 |
| CAR-T product | .001 | ||
| Tisa-cel | 478 | 1 | |
| Axi-cel | 1424 | 2.11 (1.36–3.29) | .001 |
| Rapid Onset of CRS (≤4 days versus >4 days CRS or no CRS) | |||
| Elevated LDH prior to CAR-T | <.001 | ||
| No | 722 | 1 | |
| Yes | 832 | 1.67 (1.36–2.05) | <.001 |
| Not reported | 352 | 1.25 (0.96–1.63) | .095 |
| CAR-T product | .001 | ||
| Tisa-cel | 478 | 1 | |
| Axi-cel | 1428 | 1.46 (1.17–1.81) | .001 |
| ICANS (no versus yes) | |||
| Age | <.0001 | ||
| <65 years | 1057 | 1.00 | |
| ≥65 years | 835 | 1.83 (1.50–2.24) | <.0001 |
| KPS prior to CAR-T | <.0001 | ||
| 90–100 | 733 | 1.00 | |
| 80 | 542 | 1.17 (0.92–1.49) | .19 |
| <80 | 371 | 2.48 (1.88–3.27) | <.0001 |
| Not reported | 246 | 1.52 (1.11–2.09) | .01 |
| Disease status at infusion | |||
| Complete response | 72 | 1.00 | .0001 |
| Partial response | 434 | 1.30 (0.70–2.41) | .40 |
| Resistant | 1222 | 1.98 (1.10–3.58) | .02 |
| Untreated/not reported | 164 | 2.62 (1.35–5.10) | .004 |
| CAR-T product | <.0001 | ||
| Tisa-cel | 478 | 1.00 | |
| Axi-cel | 1414 | 5.85 (4.48–7.64) | <.0001 |
| Severe ICANS (≥3 grade versus <3 grade and no ICANS) | |||
| Age | .0003 | ||
| <65 years | 1029 | 1.00 | |
| ≥65 years | 810 | 1.56 (1.22–1.98) | .0003 |
| KPS prior to CAR-T | <.0001 | ||
| 90–100 | 713 | 1.00 | |
| 80 | 533 | 1.24 (0.90–1.70) | .18 |
| <80 | 356 | 2.85 (2.07–3.93) | <.0001 |
| Not reported | 237 | 2.76 (1.91–3.99) | <.0001 |
| Elevated LDH prior to CAR-T | .007 | ||
| No | 694 | 1.00 | |
| Yes | 799 | 1.52 (1.15–2.00) | .003 |
| Not reported | 346 | 1.09 (0.77–1.55) | .62 |
| CAR-T product | <.0001 | ||
| Tisa-cel | 478 | 1.00 | |
| Axi-cel | 1361 | 5.65 (3.82–8.35) | <.0001 |
| Rapid Onset ICANS (≤7 days versus >7 days ICANS and no ICANS) | |||
| Age | <.0001 | ||
| <65 years | 1057 | 1.00 | |
| ≥65 years | 835 | 1.73 (1.40–2.15) | <.0001 |
| KPS prior to CAR-T | <.0001 | ||
| 90–100 | 733 | 1.00 | |
| 80 | 542 | 1.19 (0.91–1.55) | .21 |
| <80 | 371 | 2.07 (1.56–2.76) | <.0001 |
| Not reported | 246 | 1.45 (1.03–2.05) | .04 |
| Elevated LDH prior to CAR-T | .0055 | ||
| No | 718 | 1.00 | |
| Yes | 821 | 1.40 (1.10–1.79) | .006 |
| Not reported | 353 | 0.97 (0.71–1.32) | .82 |
| CAR-T product | <.0001 | ||
| Tisa-cel | 478 | 1.00 | |
| Axi-cel | 1414 | 4.02 (2.95–5.49) | <.0001 |
axi-cel indicates axicabtagene ciloleucel; CAR-T, chimeric antigen receptor T cell therapy; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; LDH, lactate dehydrogenase; KPS, Karnofsky Performance Status; OR, odds ratio; tisa-cel, tisagenlecleucel.